Chartwell Investment Partners LLC Grows Holdings in Boston Scientific Co. (NYSE:BSX)

Chartwell Investment Partners LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 0.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 172,545 shares of the medical equipment provider’s stock after acquiring an additional 267 shares during the period. Chartwell Investment Partners LLC’s holdings in Boston Scientific were worth $6,058,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Blue Fin Capital Inc. boosted its stake in Boston Scientific by 4.2% in the 1st quarter. Blue Fin Capital Inc. now owns 7,462 shares of the medical equipment provider’s stock worth $243,000 after buying an additional 300 shares during the last quarter. Jacobi Capital Management LLC boosted its position in shares of Boston Scientific by 10.0% in the second quarter. Jacobi Capital Management LLC now owns 3,300 shares of the medical equipment provider’s stock worth $116,000 after acquiring an additional 300 shares during the last quarter. Financial Counselors Inc. grew its holdings in Boston Scientific by 2.8% in the first quarter. Financial Counselors Inc. now owns 11,113 shares of the medical equipment provider’s stock valued at $363,000 after purchasing an additional 304 shares during the period. Global Retirement Partners LLC increased its position in Boston Scientific by 75.0% during the second quarter. Global Retirement Partners LLC now owns 714 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 306 shares during the last quarter. Finally, Raymond James Trust N.A. raised its stake in Boston Scientific by 2.7% during the second quarter. Raymond James Trust N.A. now owns 11,750 shares of the medical equipment provider’s stock worth $412,000 after purchasing an additional 310 shares during the period. 89.97% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE BSX opened at $38.57 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.80 and a current ratio of 1.21. Boston Scientific Co. has a 1 year low of $24.10 and a 1 year high of $46.62. The stock’s 50-day simple moving average is $36.11 and its 200-day simple moving average is $37.19. The firm has a market cap of $53.97 billion, a price-to-earnings ratio of 13.68, a PEG ratio of 3.94 and a beta of 0.92.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.12. Boston Scientific had a return on equity of 13.68% and a net margin of 39.18%. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $1.68 billion. During the same quarter last year, the firm earned $0.39 EPS. Boston Scientific’s quarterly revenue was down 23.9% on a year-over-year basis. As a group, research analysts predict that Boston Scientific Co. will post 0.93 EPS for the current year.

In related news, EVP David A. Pierce sold 2,170 shares of Boston Scientific stock in a transaction on Wednesday, July 22nd. The shares were sold at an average price of $38.00, for a total value of $82,460.00. Following the completion of the sale, the executive vice president now owns 9,401 shares in the company, valued at $357,238. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.70% of the stock is currently owned by company insiders.

A number of analysts have recently commented on BSX shares. Wells Fargo & Co upped their price objective on Boston Scientific from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Stifel Nicolaus upped their price target on Boston Scientific from $45.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday. Raymond James lifted their price objective on Boston Scientific from $42.00 to $43.00 and gave the company a “strong-buy” rating in a research note on Thursday, April 30th. SunTrust Banks cut their price target on shares of Boston Scientific from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, April 23rd. Finally, UBS Group decreased their price objective on shares of Boston Scientific from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company’s stock. Boston Scientific currently has an average rating of “Buy” and an average price target of $44.71.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

See Also: What kind of dividend yield to CEF’s pay?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.